Andrea Discacciati
Overview
Explore the profile of Andrea Discacciati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lantz A, Nordlund P, Falagario U, Jaderling F, Ozbek O, Clements M, et al.
Eur Urol Open Sci
. 2023 Apr;
51:89-94.
PMID: 37091033
The aim of focal treatments (FTs) in prostate cancer (PCa) is to treat lesions while preserving surrounding benign tissue and anatomic structures. Irreversible electroporation (IRE) is a nonthermal technique that...
12.
Hao S, Discacciati A, Eklund M, Heintz E, Ostensson E, Elfstrom K, et al.
JAMA Oncol
. 2022 Nov;
PMID: 36355382
Importance: The combination of prostate-specific antigen (PSA) testing with magnetic resonance imaging (MRI) for prostate cancer detection has rarely been evaluated in a screening context. The STHLM3-MRI screening-by-invitation study (NCT03377881)...
13.
Files D, Matthay M, Calfee C, Aggarwal N, Asare A, Beitler J, et al.
BMJ Open
. 2022 Jun;
12(6):e060664.
PMID: 35667714
Introduction: The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with...
14.
Bjornebo L, Nordstrom T, Discacciati A, Palsdottir T, Aly M, Gronberg H, et al.
JAMA Oncol
. 2022 May;
8(7):1019-1026.
PMID: 35587340
Importance: There is evidence that 5α-reductase inhibitors (5-ARIs), a standard treatment of benign prostate hyperplasia, are associated with a decrease in the incidence of prostate cancer (PCa). However, studies to...
15.
Hao S, Heintz E, Ostensson E, Discacciati A, Jaderling F, Gronberg H, et al.
Eur Urol
. 2022 Apr;
82(1):e21.
PMID: 35367086
No abstract available.
16.
De Laere B, Crippa A, Discacciati A, Larsson B, Oldenburg J, Mortezavi A, et al.
Eur Urol Focus
. 2022 Mar;
8(6):1617-1621.
PMID: 35317973
ProBio is an outcome-adaptive, multiarm, multiple-assignment randomised, biomarker-driven platform trial in men with metastatic castration-resistant prostate cancer. Here we describe the amended clinical protocol, focusing on expansion of the trial...
17.
Hao S, Heintz E, Ostensson E, Discacciati A, Jaderling F, Gronberg H, et al.
Eur Urol
. 2022 Jan;
82(1):12-19.
PMID: 35094896
Background: Stockholm3 is a risk model that combines the prostate-specific antigen (PSA) test, other plasma protein biomarkers, single nucleotide polymorphisms, and clinical variables. The STHLM3-MRI study (NCT03377881) found that the...
18.
Eklund M, Discacciati A, Nordstrom T
N Engl J Med
. 2021 Nov;
385(22):2110-2111.
PMID: 34818498
No abstract available.
19.
Nordstrom T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, et al.
Lancet Oncol
. 2021 Aug;
22(9):1240-1249.
PMID: 34391509
Background: Screening for prostate cancer using prostate-specific antigen (PSA) reduces prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a traditional screening approach with a diagnostic...
20.
Eklund M, Jaderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al.
N Engl J Med
. 2021 Jul;
385(10):908-920.
PMID: 34237810
Background: High rates of overdiagnosis are a critical barrier to organized prostate cancer screening. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address this challenge, but...